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Abstract
Nemaline myopathy (NM) caused by mutations in the gene encoding nebulin (NEB) accounts for at least 50% of all
NM cases worldwide, representing a significant disease burden. Most NEB-NM patients have autosomal recessive
disease due to a compound heterozygous genotype. Of the few murine models developed for NEB-NM, most are
Neb knockout models rather than harbouring Neb mutations. Additionally, some models have a very severe
phenotype that limits their application for evaluating disease progression and potential therapies. No existing
murine models possess compound heterozygous Neb mutations that reflect the genotype and resulting phenotype
present in most patients. We aimed to develop a murine model that more closely matched the underlying genetics
of NEB-NM, which could assist elucidation of the pathogenetic mechanisms underlying the disease. Here, we have
characterised a mouse strain with compound heterozygous Neb mutations; one missense (p.Tyr2303His), affecting a
conserved actin-binding site and one nonsense mutation (p.Tyr935*), introducing a premature stop codon early in
the protein. Our studies reveal that this compound heterozygous model, NebY2303H, Y935X, has striking skeletal
muscle pathology including nemaline bodies. In vitro whole muscle and single myofibre physiology studies also
demonstrate functional perturbations. However, no reduction in lifespan was noted. Therefore, NebY2303H,Y935X mice
recapitulate human NEB-NM and are a much needed addition to the NEB-NM mouse model collection. The
moderate phenotype also makes this an appropriate model for studying NEB-NM pathogenesis, and could
potentially be suitable for testing therapeutic applications.
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Introduction
Nemaline myopathy (NM) is one of the most common
congenital myopathies and is caused by pathogenic vari-
ants in one of at least twelve different genes [4, 18, 27,
29, 37, 52, 55, 64, 69, 74, 75, 91]. Patient muscle biopsies
show accumulation of Z-disc and thin filament associ-
ated proteins into aggregates called nemaline bodies,
usually accompanied by disorganization of the muscle Z
discs [14, 80, 83]. There can be large variation in clinical
severity, from in utero presentation and early neonatal
death, through to milder forms with later onset [77, 86].
Autosomal recessive NM is most commonly caused by
pathogenic variants in the nebulin gene (NEB; NEM2,
Online Mendelian Inheritance in Man #256030) [44].
While the clinical severity varies from severe, early onset
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forms through to milder forms, NEB-NM most often
presents as a slowly progressive disease, with weakness
in proximal skeletal muscles and potential later involve-
ment of distal muscles [77]. Appropriate respiratory
management usually results in a normal lifespan [73].
To date, over 200 NM-causing pathogenic variants have
been identified throughout the entire length of NEB [32,
44, 64, 65]. Variants in NEB can also cause disorders de-
scribed as distal nebulin myopathy [84], distal NM [45],
foetal akinesia/lethal multiple pterygium syndrome [1,
44] and, in rare cases, core-rod myopathy [71].
NEB is comprised of 183 exons that encode a theoretical
26 kb full-length mRNA, although extensive alternative
splicing results in a wide variety of different transcripts
[19, 38]. Nebulin is a giant (600–900 kDa) actin-binding
protein, with the C-terminus located deep within the Z
disc whilst the rest of the protein stretches nearly the en-
tire length of the thin filament of the skeletal muscle
sarcomere [36]. It is thought to stabilise, stiffen and
strengthen actin filaments, specify minimum thin-filament
length as well as regulate Z-disc width and intermyofibril-
lar connectivity through its interaction with multiple pro-
teins, e.g. desmin, titin and myopalladin [8, 13, 31, 34, 62,
81, 89]. Recently it has also been shown that nebulin con-
tributes to thin filament activation and cross-bridge re-
cruitment [34]. Although these multiple roles for nebulin
have been suggested, many known and potential aspects
of its function are still to be understood. For example, the
dynamic movement of nebulin and its interaction partners
in the thin filament during muscle contraction remains
unclear [13, 88]. Furthermore, the nebulin transcript is al-
ternatively spliced to produce alternative protein isoforms
(for example super repeat S21 in isoforms a and b; see our
recent report [40]). The functional importance of the dif-
ferent isoforms is currently under investigation.
Despite the large number of pathogenic variants identi-
fied in NEB, no clear mutational hotspots or genotype-
phenotype correlations have been found [44], and the
functional significance of disease-causing variants are
largely unknown. Most NEB-NM patients have a com-
pound heterozygous genotype and, if one of the two vari-
ants is missense, then the other is a more disruptive variant
such as a nonsense variant or a deletion/insertion [44].
Interestingly, the same variant has been identified in pa-
tients with diverse clinical severities, or even with different
myopathies [44]. As such, an appropriate model organism
is required to better understand the complex pathogenetic
mechanisms that underlie the diverse forms of NM. Such a
model would also enable potential therapies to be tested in
a system that recapitulates the human disease.
A number of murine models have been published [8,
25, 46, 47, 61, 89, 90], and have each provided new
knowledge about nebulin function and the potential
pathogenesis of NM. However, none of these models
possess a compound heterozygous genotype that would
be representative of most human NEB-NM cases. Fur-
thermore, there are currently no Neb models that recap-
itulate the most common phenotype of NEB-NM.
Therefore, we have produced a murine model with com-
pound heterozygous Neb variants; a missense variant
(p.Tyr2303His) in the perfectly conserved tyrosine resi-
due in an actin-binding site, and a nonsense variant
(p.Tyr935*) introducing a premature stop codon in the
beginning of the super-repeat region. Our aims were to
characterise this new murine model, and to investigate




Mouse lines with a C57BL/6J background carrying either
the NebY2303H or the NebY935X variant were selected from a
missense mutation library derived from N-ethyl-N-nitro-
sourea (ENU) mutagenesis (Australian Phenomics Facility,
Australian National University, Canberra [5]) on the basis of
their potential pathogenicity. The missense variant NP_
035019.1:p.(Tyr2303His), c.6907T >C (NM_010889.1),
changed the perfectly conserved amino acid tyrosine (Y,
Tyr) in the last actin-binding site (SDxxYK) of the eighth
super repeat (S8). The nonsense variant NP_035019.1:
p.(Tyr935*), c.2805C >G, introduced a premature stop
codon in the third super repeat (S3), which was expected to
lead to nonsense-mediated RNA decay. To maintain the
parental lines, mice heterozygous for each variant, either
C57BL/6J-NebY2303H(+/−) or C57BL/6J-NebY935X(+/−), were
bred with heterozygous mice of the same genotype, giving
rise to homozygous, heterozygous and wild-type genotypes.
Resulting mice that were heterozygous for each variant were
bred together to generate compound heterozygous mice
C57BL/6J-NebY2303H(+/−),Y935X(+/−), hereafter annotated
NebY2303H,Y935X. This breeding regime was chosen as homo-
zygous mice for the missense mutation (NebY2303H(+/+)) were
less fertile than those that were heterozygous
(NebY2303H(+/−)), and mice homozygous for the nonsense
variant (NebY935X(+/+)) were not viable. NebY2303H,Y935X mice
were compared against wild-type littermates or age- and
sex-matched C57BL/6J mice.
Mice were housed in a pathogen-free facility at the
Animal Resources Centre (Murdoch, Western Australia)
and were cared for according to guidelines set by the
National Health and Medical Research Council of
Australia. Rooms were on a 15:9 h light/dark cycle and
mice had ad libitum access to tap water and a regular
diet (Specialty Feeds, Western Australia).
Experimentation was approved by the Animal Ethics
Committees of the Animal Resources Centre and The
University of Western Australia.
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In vivo phenotypic tests
The compound heterozygous NebY2303H,Y935X mice, and
the heterozygous NebY2303H(+/−) and NebY935X(+/−) mice
were analysed against wild-type littermate controls of
the same age and sex. Bodyweight was measured at 3
and 6months.
Voluntary exercise
Mice were housed individually with access to voluntary
low-profile wireless running wheels (ENV-044, Med As-
sociates Inc., Fairfax, VT, USA) for 6 consecutive days at
3 and 6months of age. A wireless USB Interface Hub
(DIG-804, Med Associates) was used to collect wheel
data that were viewed and extracted using Wheel Man-
ager (SOF-860, Med Associates). Four parameters were
calculated for daily performance, including: daily dis-
tance travelled, time spent running, average speed and
maximum speed. Only data from days 4 to 6 were
used for analysis to allow for initial acclimatisation to
the wheel.
Grip strength
At 3 and 6months of age, each mouse was lifted by its
tail until its front paws were in line with the bar of the
grip strength meter (Bioseb, Vitrolles, France). Mice
were then allowed to reach out to the bar before being
gently pulled away at a slow, constant speed. This
allowed mice to build up resistance until the grasp was
finally broken, at which point the grip strength value (N)
was recorded. The test was repeated three times for each
mouse. Measurements were discarded if the mouse used
only one paw, also used its hind paws, turned backwards
during the pull, or left the bar without resistance.
Rotarod
The day before testing (or as close as possible), mice
were acclimatised to the rotarod (Ugo Basile 47,600,
Schwenksville, PA, USA) by training for 2 min with slow
rod rotation (4 rpm). Mice that fell off during this period
were replaced onto the rod until the full time had
elapsed. To test performance, mice were placed on the
rotarod set at 4 rpm with speed of rotation gradually in-
creased to a maximum of 60 rpm over a period of 3 min.
The latency (time to fall) and the speed at this point
were recorded. Mice that fell off within the first 10 s
were re-tested after a rest of at least 10 min. However,
mice did not get re-tested if they performed a passive ro-
tation (the mouse held on and spun around the rod).
When mice did not fall off the rotarod after 5 min, the
experiment was ceased. The test was repeated three
times within the same session, with each mouse given at
least 5 min to rest between each test.
Transcript level
Neb transcript expression in 9–12 month-old gastrocne-
mius samples from female NebY2303H,Y935X mice was
compared with expression in the parental lines
(NebY2303H(+/+), NebY2303H(+/−) and NebY935X(+/−)) and the
C57BL/6J background strain. Skeletal muscle samples
from NebY935X(+/+) mice were not included due to their
embryonic or early neonatal death, and also as the focus
of this study was characterising the compound heterozy-
gous Neb mutant mice.
RNA extraction and cDNA synthesis
Snap frozen gastrocnemius muscles were divided longitu-
dinally, and half (~ 20–30mg) was homogenised in 300 μl
Buffer RLT with β-mercaptoethanol using a BioSpec mini-
bead beater (maximum oscillations per min at 30 s inter-
vals). RNA was subsequently extracted using an RNeasy
fibrous tissue mini kit with on-column DNase I treatment
(QIAGEN, USA). RNA yield was determined using a Nano-
drop ND-1000 spectrophotometer and quality assessed on
a 1% agarose gel. Up to 1 μg of RNA was used for cDNA
synthesis using the SuperScript III first-strand synthesis sys-
tem with random hexamer primers (Thermo Fisher, USA).
Samples were diluted tenfold for 1 μg of starting RNA and
scaled accordingly for lower input quantities.
Quantitative RT-PCR
Transcript abundance of target genes was determined by
quantitative reverse-transcriptase PCR (qRT-PCR) using
the Rotor-Gene SYBR Green PCR kit (QIAGEN, USA)
and a Rotor-Gene Q cycler (QIAGEN, USA). Reactions
were performed in 10 μl volumes with 0.8 μM primers
and 1 μl diluted cDNA.
The relative abundance of mutant (p.Tyr2303His, c.6907
T >C, C allele) and wild-type (T allele) Neb transcripts was
determined using allele-specific qRT-PCR. Forward primers
were specific for either the wild-type (5′- GGACATTGCT
AGTGACTTTAAAT) or Tyr2303His mutant allele (5′-
GGACATTGCTAGTGACTTTAAAC) and used in
combination with a non-distinguishing reverse primer (5′-
CACAGGGCTGGTGTATTTGG). The wild-type allele-
specific forward primer also detected transcripts from the
mutant p.Tyr935* allele. Standards for assessment of qPCR
efficiency were generated by serial dilution of cDNA of the
respective genotypes. Cycling conditions were as follows:
95 °C for 5min, 45 cycles of 95 °C for 10 s and 62 °C for 15
s, followed by melt curve analysis.
Relative abundance was calculated using the ΔCt method
with Tbp (F: 5′-ATCTACCGTGAATCTTGGCTGT, R: 5′-
TGTTCTTCACTCTTGGCTCCTG) and Eef2 (F: 5′-
AGAAAGCCAACATCCGGAACA, R: 5′-GATGGC
GGTGGATTTGATTGT) for normalisation. Cycling condi-
tions were as follows: 95 °C for 5min, 45 cycles of 95 °C for
10 s and 60 °C for 15 s, followed by melt curve analysis.
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Protein electrophoresis
Nebulin protein content was analysed using the 1% SDS
agarose gel method [66]. Quadriceps muscle tissue from
three female mice per genotype was ground to a fine
powder using Dounce homogenisers cooled in liquid ni-
trogen and acclimated to − 20 °C for 30 min. Tissue
powder was resuspended in a 1:1 mixture of an 8M urea
buffer (in M; 8 urea, 2 thiourea, 0.05 Tris-HCl, 0.075 di-
thiothreitol, as well as 3% SDS and 0.03% bromophenol
blue, pH 6.8) and 50% glycerol containing protease in-
hibitors (in mM; 0.04 E-64, 0.16 leupeptin, and 0.2
PMSF). Tissue powder was homogenised in solution for
4 min, followed by a 10min incubation at 60 °C. Samples
were centrifuged at 12,000 rpm and the supernatant was
divided into smaller aliquots and flash frozen for storage
at − 80 °C. SDS-agarose (SDS-AGE) 1% gels, run in a
Hoefer SE600X vertical gel system (Hoefer Inc.; Hollis-
ton, USA), were used to electrophoretically separate
nebulin from other proteins, such as titin and myosin
heavy chain. The samples were run in five incremental
loading volumes. Gels were run at 15 mA per gel for 3 h
and 15min, then stained using Neuhoff’s Coomassie
staining protocol and scanned using a commercial scan-
ner (Epson 800, Epson Corporation, Long Beach CA).
Nebulin expression was quantified from the gel images
and normalised against myosin heavy chain abundance
in each lane.
Histology and immunostaining
Extensor digitorum longus (EDL), soleus (SOL), tibialis
anterior, gastrocnemius, quadriceps femoris, diaphragm,
and masseter skeletal muscles were selected on the basis
of their suitability for the studies and potential involve-
ment in NEB-NM. The muscles were collected from
mice aged 4 to 12 months and snap frozen in isopentane
cooled with liquid nitrogen. Sections of 8–10 μm were
cut on a Leica CM3050S cryostat, then stained with
haematoxylin and eosin (H&E), Gomori trichrome or
succinate dehydrogenase (SDH) using standard histo-
chemical techniques [20].
Muscle sections of 10 μm were fixed in 2% paraformal-
dehyde (PFA), blocked in phosphate buffered saline
(PBS) with 10% foetal calf serum (FCS; Gibco), 1% bo-
vine serum albumin (BSA; Sigma) and 1% saponin
(Sigma) for 1 h. Mouse monoclonal antibody SERCA1
ATPase (diluted 1:1000, MA3–911, ThermoFisher) was
conjugated to Zenon® Alexa Fluor® 594 (Life Technolo-
gies) and incubated with phalloidin-fluorescein isothio-
cyanate (diluted 1:1000; P5282, Sigma), at 4 °C
overnight. Phalloidin tetramethylrhodamine was used
alone (diluted 1:100, P1951, Sigma). Slides were washed
in PBS, counterstained in Hoechst (Sigma) and mounted
in Fluoromount (Sigma). Muscle sections to be incu-
bated with mouse monoclonal alpha-actinin (diluted 1:
10, EA-53, Sigma) followed the same protocol as above,
however, sections were not fixed and saponin was omit-
ted from the blocking solution.
Immunostaining for fibre typing
Muscle sections of 9-month-old NebY2303H,Y935X and age
matched wild-type littermates were labelled as described
previously [54]. Briefly, after blocking, mouse IgG1 anti-
bodies against myosin heavy chain MHCI (slow myosin
I; diluted 1:20, NCL-MHCs, Leica Biosystems) or
MHCIIA (fast myosin IIA; diluted 1:5, SC-71, DSHB)
were conjugated to Zenon® Alexa Fluor® 594 (Life Tech-
nologies). Primary mouse IgM antibody MHCIIB (fast
myosin IIB; diluted 1:10, BF-F3, DSHB) was then added
and incubated at 4 °C overnight. The secondary antibody
Zenon® Alexa Fluor® 488 anti-mouse IgM was sequen-
tially incubated at room temperature for 60 min. Slides
were washed in PBS, counterstained in Hoescht (Sigma)
and mounted in Fluoromount (Sigma).
Myofibre sizes and fibre type proportions
Fibre typing of the soleus and extensor digitorum longus
muscles was conducted on merged images showing (1)
MHCI with MHCIIA, and (2) MHCIIA with MHCIIB
(see immunostaining for methods). Fibres of each differ-
ent type were counted and the Feret’s diameter mea-
sured using ImageJ software (various versions; US
National Institute of Health, USA).
Electron microscopy
Extensor digitorum longus, soleus, tibialis anterior,
gastrocnemius, quadriceps femoris and masseter skeletal
muscles from 4 to 9-month-old NebY2303H,Y935X and age
matched wild-type littermates were prepared for electron
microscopy to assess their ultrastructure. After excision,
the muscle was immersed in 2.5% phosphate buffered
glutaraldehyde. Tissue was cut into approximately 2 × 1
mm strips and processed using a Leica tissue processor,
immersed in 1% aqueous osmium tetroxide, graduated
ethanols, propylene oxide, followed by araldite resin.
Blocks were polymerised in a 70 °C oven overnight.
Thin sections were cut on an ultratome (RMC
Boeckeler) and stained after drying on copper grids
with saturated aqueous uranyl acetate and lead citrate
according to standard techniques. The images were
captured using a GATAN Orius 11 megapixel digital
camera attached to a JEOL 1400 transmission electron
microscope.
Whole muscle physiology
Seven-month-old (± 6 days) male mice were anaes-
thetised (pentobarbitone via intraperitoneal injection,
40 mg/kg body weight) and the extensor digitorum
longus (EDL) and soleus (SOL) surgically excised
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and mounted onto an in vitro muscle test system
(model 1205A; Aurora Scientific Inc.). Muscles were
maintained in an organ bath filled with Krebs mam-
malian ringer solution (121 mM NaCl, 5.4 mM KCl,
1.2 mM MgSO4.7H2O, 25 mM NaHCO3, 5 mM
HEPES, 11.5 mM glucose and 2.5 mM CaCl2, pH 7.3),
bubbled with carbogen (5% CO2 in O2) and main-
tained at 25 °C [7].
Isolated muscles were manually adjusted to the opti-
mal muscle length (Lo), which was determined as the
muscle length that produced maximum twitch force.
The twitch time-course was quantitated by measuring
contraction time (time-to-peak), maximum rate of force
development (max dF/dt) and half-relaxation time. The
force-stimulation frequency relationship was established
by exposing muscles to stimulation frequencies of 10,
20, 30, 40, 60, 70, 80, 100, 120, 150 and 200 Hz (EDL),
or 5, 10, 15, 20, 30, 40, 60, 80, 100 and 120 Hz (SOL).
Muscles were given a 2 min rest period beween stimula-
tions to prevent fatigue affecting force output. The sus-
ceptibility of muscles to eccentric damage was
determined by exposing muscles to five sequential ec-
centric contractions, where muscles were stimulated
maximally (EDL, 120 Hz; SOL, 80 Hz) for 1 s while being
stretched to 105, 110, 120, 130 and 140% of optimal
myofibre length at a constant velocity of 1 Los
− 1. In each
eccentric contraction, an initial isometric contraction
was induced, and when isometric force had plateaued,
the muscle was stretched. A brief, transient increase in
force peak occurs at the onset of the stretch, and the
height of this transient response was measured (peak
stretch-induced force minus isometric plateau force) to
provide information about the stiffness of the muscle,
with stiffer muscle preparations producing higher transi-
ent force peaks. The amplitude of the transient stretch-
related force response was normalised to the amplitude
of the preceeding isometric phase of the contraction (%
of isometric plateau force amplitude) [68]. In order to
determine the force deficit occurring due to eccentric
contraction-induced damage, a maximal isometric con-
traction was performed before and after each eccentric
contraction and the amplitude of these maximal con-
tractions was compared [41].
At the end of the experiment, muscles were removed
from the organ bath, stripped of tendons, blotted and
weighed. Muscle cross-sectional area (CSA) was deter-
mined by dividing muscle wet mass (mg) by the product
of the optimal myofibre length and mammalian skeletal
muscle density (1.056 mg/mm3) [51]. Optimal myofibre
length was calculated by multiplying Lo by a pre-
determined myofibre to muscle length ratio for the EDL
(0.44) and SOL (0.71) [11]. The specific force (force nor-
malised to muscle cross-sectional area, N/cm2) was cal-
culated by dividing isometric force by the CSA.
Single myofibre physiology
Myofibre permeabilisation
Relaxing and activating solutions contained 4 mMMg-
ATP, 1 mM free Mg2+, 20 mM imidazole, 7 mM EGTA,
14.5 mM creatine phosphate, and KCl to adjust the ionic
strength to 180 mM and pH to 7.0. The concentrations
of free Ca2+ were 10–9.00 M (relaxing solution) and 10–
4.50 M (activating solution).
After excision, the tibialis anterior muscles from 6-
month-old male mice were placed in relaxing solution at
4 °C. Bundles of ~ 50 myofibres were dissected free and
tied with surgical silk to glass capillary tubes at slightly
stretched lengths. Bundles were treated with skinning
solution (relaxing solution with glycerol; 50:50 v/v) for
24 h at 4 °C, and transferred to − 20 °C. For long-term
storage muscle bundles were treated with sucrose, a
cryoprotectant, and within 1–2 weeks detached from the
capillary tubes, snap frozen in liquid nitrogen-chilled
isopentane and stored at − 80 °C [24].
Single myofibre force mechanics
On the day of experiment, bundles were de-sucrosed,
transferred to a relaxing solution, and single myofibres
dissected. Myofibres were individually attached between
connectors leading to a force transducer (model 400A;
Aurora Scientific) and a lever arm system (model 308B;
Aurora Scientific). Sarcomere length was set to ~
2.50 μm and the temperature to 15 °C [48, 49, 60]. Myo-
fibre CSA was approximated from width and depth
measures, assuming an elliptical circumference. Absolute
maximal isometric force generation was calculated as
the difference between the total tension in the activating
solution (pCa 4.50) and the resting tension measured for
the same myofibre in relaxing solution. Specific force
was defined as absolute force divided by CSA.
Apparent rate constants of force redevelopment (ktr)
were measured using a mechanical slack-restretch man-
oeuver. Briefly, each myofibre was transferred from
relaxing solution to activating solution and allowed to
generate steady-state force. The myofibre was then rap-
idly slackened (within 1–2 ms) by 20% of its original
length, resulting in a rapid reduction of force to near
zero. This was followed by a brief period of unloaded
shortening (20 ms) before rapidly re-stretching to its ori-
ginal length [10]. ktr was approximated by linear trans-
formation of the half-time of force redevelopment (ktr =
0.693/t1/2) as described previously [70].
Maximum unloaded shortening velocity (V0) was also
calculated by the slack test. Once steady-state isometric
force was reached, nine slacks of various amplitudes were
rapidly introduced (within 1–2ms) at one end of the myo-
fibre [22]. Slacks were applied at different amplitudes ran-
ging from 7 to 13% of the myofibre length [58, 59]. The
myofibre was re-extended between releases (while relaxed)
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in order to minimize changes to sarcomere length. The
time required to take up the imposed release was mea-
sured from the onset of the length step to the beginning
of the tension redevelopment. A straight line was fitted to
a plot of release length versus time, using least-squares re-
gression from at least four data points. V0 for each myofi-
bre segment was calculated by dividing the line slope by
the myofibre segment length [22].
Myofilament measurements
On the day of experimentation, single myofibres were
de-sucrosed, and individually dissected. Arrays of ap-
proximately nine myofibres were prepared at room
temperature (RT) and used to measure thin and thick
filament lengths. For each myofibre, both ends were
clamped to half-split copper meshes designed for elec-
tron microscopy (SPI G100 2010C-XA, width, 3 mm)
that were glued to cover slips (Menzel-Gläser, 22 × 50
mm, thickness 0.13–0.16 mm).
Myofibres were fixed in 4% PFA and permeabilised
with 0.1% Triton X-100 in PBS. Tissues were blocked in
10% goat serum/PBS before incubation with primary
antibodies diluted in goat serum blocking solution. Tro-
pomodulin 4 (Tmod4) was detected using a rabbit IgG
anti-TMOD4 antibody (1:100; R3577bl3c [26]) and α-
actinin with a mouse IgG1 anti-α-actinin antibody (1:
500; Clone EA-53, Abcam). For thin filament length
measurements, myofibres were treated with Alexa 594-
conjugated phalloidin (1:100, Molecular Probes). For
detection, tissues were incubated with Alexa 488- or
594-conjugated secondary antibodies/PBS (1:1000; Mo-
lecular Probes).
Images were collected using a CellVoyager™ (CV1000)
Confocal Scanner Box microscope using a 60x oil object-
ive lens. The CV100 software was used for image collec-
tion and the myofibres were analysed using Distributed
Deconvolution (DDecon) [56].
Statistical analyses
The unpaired Mann-Whitney, unpaired t-test, and
Welch’s t-test or two-way ANOVA were used for statis-
tical comparison of datasets, with p-values < 0.05 consid-
ered to be statistically significant. Fibre typing and whole
muscle physiology data are presented as mean ± SEM,
and the rest of the data are presented as mean ± SD.
Results
NebY2303H,Y935X mice do not have an apparent shorter
lifespan than wild-type mice
Compound heterozygous mice (NebY2303H,Y935X) were
produced at an occurrence of approximately one in eight
offspring, as expected by Mendelian ratios. Limited
numbers of NebY935X(+/+) mice were born, well below
proportions expected by Mendelian ratios, and mice
with this genotype all died by 5 days after birth. The life-
span of NebY2303H and NebY2303H,Y935X mice was not
overtly reduced, as all survived past the oldest time point
in this study (12 months), unless sacrificed earlier.
NebY2303H,Y935X mice express the p.Tyr2303His Neb allele
at ~ 50% of normal RNA levels, while the p.Tyr935*
transcript is not detected (Fig. 1a-c)
In order to ascertain the effects of the p.Tyr935* and
p.Tyr2303His variants (Fig. 1a) on transcript abundance
we performed two sets of qPCR reactions. The first qPCR
was designed to detect the presence of the wild-type (WT)
allele (but not amplify the p.Tyr2303His allele) and is pre-
sented as a percentage of WT levels (with C57BL/6J repre-
senting 100%). Since the primers were designed after the
p.Tyr935* stop codon, full length Neb transcript produced
from the p.Tyr935* allele (if any) would also be detected.
It was hypothesised that the p.Tyr935* variant would re-
sult in nonsense-mediated mRNA decay. Accordingly,
heterozygous NebY935X(+/−) mice expressed Neb at ~ 50%
of WT levels suggesting that the p.Tyr935* allele is indeed
degraded (Fig. 1b). Similarly, mice that were heterozygous
for the p.Tyr2303His variant (NebY2303H(+/−)) expressed
WT Neb at 50% of control WT levels (Fig. 1b). Negligible
off-target priming (WT) was detected in NebY2303H,Y935X
and NebY2303H(+/+) samples (Fig. 1b), which is indicative of
the specificity of this reaction as these two genotypes
should not express any WT Neb transcript.
The second qPCR was performed with primers de-
signed to detect only the p.Tyr2303His allele and the re-
sults are presented as a percentage relative to
p.Tyr2303His homozygous samples (e.g. 100% mutant).
In line with the expected consequences of the
p.Tyr2303His variant, muscles from compound hetero-
zygous NebY2303H,Y935X and heterozygous NebY2303H(+/−)
mice expressed the mutant p.Tyr2303His allele at ~ 50%
of the level observed in muscles from homozygous
NebY2303H(+/+) mice (Fig. 1c). Muscles from NebY935X(+/−)
and C57BL/6J mice produced negligible levels of the
p.Tyr2303His allele, as expected, due to absence of this
allele in these mice (Fig. 1c). Together these results con-
firm that NebY2303H,Y935X mice express a reduced total
abundance of Neb transcript, likely due to degradation
of the p.Tyr935* transcript, and all Neb transcript pro-
duced contains the p.Tyr2303His variant.
Nebulin protein levels remain comparable between the
strains (Fig. 1d-e)
We investigated whether nebulin protein levels were re-
flective of the nebulin transcript results detected in
C57BL/6J, NebY2303H(+/+), NebY935X(+/−) and compound
heterozygous NebY2303H,Y935X mice. Nebulin protein
levels remained comparable between all four strains ana-
lysed (Fig. 1d-e).
Laitila et al. Acta Neuropathologica Communications            (2020) 8:18 Page 6 of 19
Fig. 1 NebY2303H,Y935X mice express 50% of the Tyr2303His missense allele, while the Tyr935* nonsense transcript is not detected. a A schematic
representation of the location of the selected mutations on the nebulin protein. Primers, which differentiate between the (b) wild type (WT;
Tyr2303, T allele) and (c) missense (MUT; Tyr2303His, C allele) transcripts were used to generate allele-specific qPCRs. Relative Neb expression was
determined using the delta Ct method and normalised to the geometric mean of two endogenous control genes, Tbp and Eef2. Expression of
Neb transcript from NebY2303H,Y935X mice was compared with expression from the parental lines (NebY2303H(+/+), NebY2303H(+/−) and NebY935X(+/−))
and the C57BL/6J background strain. As expected, NebY2303H,Y935X mice expressed approximately 50% of the mutant allele p.Tyr2303His compared
with homozygous NebY2303H(+/+) mice, and no clear expression was detected of the WT Tyr2303 allele, supporting the hypothesis that the Tyr935*
transcript (carrying the Tyr2303 WT allele) is lost due to nonsense-mediate mRNA decay. The low level of WT transcript detected in NebY2303H,Y935X
and NebY2303H(+/+) samples is likely due to background amplification from the mutant allele since the WT and mutant alleles differ by only one
base-pair. d Representative image of the protein analysis on a 1% SDS agarose gel across the mouse strains, and e quantification of nebulin
protein, normalised to myosin heavy chain (MyHC). Nebulin protein levels remained comparable across genotypes, suggesting a compensational
mechanism in the NebY2303H,Y935X and NebY935X(+/−) mice from the transcript not undergoing nonsense-mediated decay. Unpaired Mann-Whitney,
n = 3, ns, p > 0.05
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Nemaline bodies, core-like structures, split myofibres,
internal nuclei and mitochondrial accumulations are
present in some muscles from NebY2303H,Y935X mice
(Fig. 2)
In order to determine whether muscles of NebY2303H,Y935X
mice exhibited similar histological features to patients
with NM, a range of skeletal muscles representing differ-
ent compositions of fast and slow myofibre proportions
were studied. Gomori trichrome and H&E staining re-
vealed large quantities of accumulations resembling nema-
line bodies characteristic of NM disease in patients
(Fig. 2a and b, white arrowheads). The accumulations
were most prominent in the gastrocnemius and quadri-
ceps of NebY2303H,Y935X mice and were less abundant in
the masseter, extensor digitorum longus and diaphragm at
all time points studied. Interestingly, no nemaline bodies
were found in soleus or tibialis anterior muscles. Phal-
loidin staining confirmed that the accumulations con-
tained filamentous actin (Fig. 2c, white arrowheads), and
these accumulations also stained positive for alpha-
actinin. SDH staining and fibre typing with MHC anti-
bodies indicated that the aggregates were predominantly
found in MHC type IIB (fast, glycolytic) fibres (Fig. 2d-f).
Tubular aggregates were also apparent in the skeletal
muscles of male mice. Although this is a non-specific
finding in older inbred male mice, male NebY2303H,Y935X
mice at 9 months of age had abundant and abnormally
large tubular aggregates, comparable to those usually
seen in male C57BL/6J mice at 18 months of age [3].
Tubular aggregates were distinguished from actin-
containing nemaline bodies by SERCA staining, as well
as SDH and phalloidin staining, as tubular aggregates
are negative for both of these markers (Fig. 2a-c).
Additional pathological features were also found in differ-
ent muscles. Of the skeletal muscles studied, core-like
structures were evident in the oxidative fibres of the tibialis
anterior (Fig. 2g-i) and masseter muscles, and occasionally
in the quadriceps (Fig. 2k). Core-like structures did not cor-
respond to areas of nemaline body aggregation, and they
stained negative with SDH staining, confirming that these
areas were devoid of mitochondria. Cores were only present
in a subset of fibres (fast and slow), and could not be con-
firmed with electron microscopy. Several split myofibres
were seen in the quadriceps (Fig. 2j-l) and extensor digi-
torum longus. Furthermore, internal nuclei and apparent
myofibre size variation were observed in the quadriceps,
but due to the heterogeneity of the quadriceps muscle,
these features were not further quantified (Fig. 2j-l).
Transmission electron microscopy of the gastrocne-
mius from NebY2303H,Y935X mice validated the presence
of electron-dense material indicative of nemaline bodies
(Fig. 3a-f, seen in aggregates and as expansions of Z-disc
structures), and tubular aggregates (Fig. 3a). The nema-
line bodies were large and irregular, and in some
instances clearly originated from the Z discs (thickened
Z discs [20], Fig. 3d-f). Large intermyofibrillar aggregates
of mitochondria were seen in a subpopulation of myofi-
bres of all skeletal muscles studied, with variation in
mitochondrial size within the aggregates (Fig. 3g-i).
NebY2303H,Y935X mice have significantly smaller myofibre
diameters (Fig. 4)
MHC fibre types (I, IIA, IIB, hybrid I/IIA and hybrid IIA/
IIX) from the extensor digitorum longus (EDL) and soleus
(SOL) of 9-month-old female NebY2303H,Y935X mice were
counted and fibre diameters measured (for the numerical
data, see Additional file 1). All myofibres that contained a
fast MHC (type IIA, IIB, IIA and/or IIX) were significantly
smaller in the EDL from NebY2303H,Y935X mice compared
with age-matched wild-type littermates. However, myofi-
bres expressing slow MHC (type I) trended towards being
hypertrophied in the EDL of NebY2303H,Y935X mice (Fig. 4a;
type I: + 19.2%, p = 0.0854, ns; type IIA: − 11.3%, p <
0.0001; type IIB: − 6.6%, p < 0.0001; type IIA/IIX: − 8.9%,
p = 0.006). All myofibres from the SOL of NebY2303H,Y935X
mice were significantly smaller (Fig. 4b; type I: − 8.4%, p <
0.0001; type IIA: − 10.6%, p < 0.0001, type IIB: − 27.6%,
p = 0.0015; type IIA/IIX: − 21.7%, p < 0.0001).
Fibre-type proportions (as % of all myofibres) in the
EDL (Fig. 4c; n = 3) and SOL (Fig. 4d; n = 3) from
NebY2303H,Y935X mice were trending towards being sig-
nificantly different when compared with wild-type litter-
mate controls. In both muscles the oxidative fibre types
(slow MHC I or fast IIA) were more abundant (EDL,
type I: + 4.68%, p = 0.4, ns; type IIA + 16.17%, p = 0.1, ns;
SOL, type I: + 13.37%, p = 0.1, ns), whereas there were
less fast twitch, glycolytic type IIB fibres (EDL, type IIB:
− 27.74%, p = 0.1, ns; SOL, type IIB: − 4.92%, p = 0.1, ns).
A predominance of slow, type I fibres is common in
NEB-NM patients [86] so it is promising that our mouse
model is displaying a similar trend.
Skeletal muscles from NebY2303H,Y935X mice are
susceptible to eccentric contraction-induced damage
(Fig. 5)
Analysis of whole muscle physiology in vitro showed twitch
contraction times were faster (reduced time-to-peak values)
in the extensor digitorum longus (EDL) muscles from
NebY2303H,Y935X mice compared with age-matched wild-
type littermate controls (p = 0.0234). No difference in soleus
(SOL) twitch contraction times was found between groups
(p = 0.0592, ns). All other twitch parameters and
maximum specific force were similar in muscles from
NebY2303H,Y935X and control mice (Additional file 2).
However, significant decreases in normalised force were
found in NebY2303H,Y935X muscles compared with wild-
type controls at low stimulation frequencies: EDL at 20Hz
(p = 0.0385) and 30Hz (p = 0.0002); SOL from 10Hz – 30
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Fig. 2 Histology and immunostaining of different skeletal muscles from NebY2303H,Y935X mice demonstrate multiple pathological features. a-c
Nemaline bodies (white arrowheads; purple staining in Gomori, and intense staining with TRITC-phalloidin) in serial cross-sections of
gastrocnemius (9-month-old male) stained with Gomori trichrome (a), H&E (b) and TRITC-phalloidin (c). Tubular aggregates (yellow arrowheads;
pink in Gomori, negative with phalloidin) are a non-specific finding in older male mice from certain inbred strains. d-e Fibre typing was
performed on serial sections using MyHC I (d), and MyHC IIA and IIB (e), antibodies. f TRITC-phalloidin visualised the actin-containing nemaline
bodies most commonly locating in the fast MyHC type IIB fibres. All myofibres containing definite nemaline bodies are indicated with an asterisk
(*), and 25/25 of these fibres are MyHC type IIB. Nemaline bodies were occasionally found in MyHC IIA fibres, however, no nemaline bodies were
found in MyHC type I (slow) fibres (all type I fibres are indicated with an “I”). g-i Cross-sections of tibialis anterior (12-month-old female) stained
with Gomori trichrome (g), SDH (h), and H&E (i), showing core-like structures in several myofibres (white arrowheads and inset). j-l Cross-sections
of quadriceps (9 month male) stained with Gomori trichrome (j), SDH (k), and TRITC-phalloidin with Hoechst (l) showing internal nuclei (white
arrowheads), split fibres (yellow arrowheads) and an occasional core-like structure (*)
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Hz (p < 0.0001), 40Hz (p = 0.0018) and 50Hz (p = 0.0307)
(Fig. 5a, b). The EDL from NebY2303H,Y935X mice was more
susceptible to eccentric contraction-induced muscle dam-
age than wild-type controls when stretched from 120 to
140% of Lo (optimal muscle length) during eccentric activa-
tion (Fig. 5c, d). According to the transient stretch-related
peak force data, the EDL muscles from NebY2303H,Y935X
mice were significantly stiffer than those from wild-type
controls (NebY2303H,Y935X EDL transient stretch response
was 20% greater than the wild-type response during 140%
of Lo stretch, p = 0.0008). In contrast, the SOL from
NebY2303H,Y935X mice exhibited a significant decrease (15%)
in stiffness during 140% of Lo stretch compared with the
wild-type response (p = 0.0283) (Fig. 5e, f).
Altered myosin cross-bridge kinetics potentially underlying
force depression in muscles from NebY2303H,Y935X mice
(Fig. 6a-c)
The single myofibre preparation allows direct measure-
ments of contractility with an intact myofilament lattice
without the confounding effects of nerves, excitation-
contraction coupling, myofibre architecture and inter-
cellular connective tissue. Tibials anterior muscles were
isolated from 6-month-old male mice and the dissected
myofibres (mainly IIX and IIB fibres) were used in the
experiments. The mean maximum specific force was 22%
lower in NebY2303H,Y935X mice than in wild-type mice (Fig.
6a, p = 0.036). Additionally, the mean ktr (rate of force
redevelopment) was 28% slower in NebY2303H,Y935X mice
(Fig. 6b; p = 0.012). The V0 (maximum unloaded shorten-
ing velocity) was unaffected in NebY2303H,Y935X mice
(Fig. 6c). Taken together, these results indicate a potential
alteration of myosin cross-bridge kinetics underlying the
force depression. ktr reflects the myosin cross-bridge cycle
turnover rate and according to the two-state cross-bridge
model, it is proportional to fapp + gapp, with fapp being the
rate constant for attachment and gapp the rate constant for
detachment. V0 has gapp as a rate limiting step. Hence, in
NebY2303H,Y935X mice the combination of decreased ktr
and maintained V0 indicates a dramatic reduction in fapp.
This is likely to shorten the time spent by each myosin
molecule in a strongly bound force-producing
Fig. 3 Ultrastructural analysis of muscles from NebY2303H,Y935X mice confirmed nemaline bodies, tubular aggregates and pleomorphic
mitochondria. a-c Electron microscopic images showing nemaline bodies (white arrowheads) and tubular aggregates (yellow arrowheads) from a
9-month-old male mouse. d-f Nemaline bodies originating from the Z disc identified in 8–12-month-old female mice. g-i Large intermyofibrillar
aggregates of mitochondria were seen in all the muscles studied, with notable variation in mitochondrial size within the aggregates
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conformation limiting the fraction of active myosin cross-
bridges. Note that fibres were not assessed for their my-
osin heavy chain composition. Hence, it is not totally
excluded that some of our results may be due to fibre type
differences.
Muscles from NebY2303H,Y935X mice have a preserved thin
filament length (Fig. 6d)
Immunostaining of single myofibres with Tmod4 and α-
actinin antibodies were used to measure sarcomeric dis-
tances. No differences in thin filament lengths were
detected over a range of sarcomere lengths (Fig. 6d) in
NebY2303H,Y935X mice compared with wild-type mice.
Alpha-actinin was correctly localised and showed regular
striation patterns, indicating preserved Z-disc structures
in NebY2303H,Y935X mice.
Assessment of exercise function revealed that
NebY2303H,Y935X mice display a mild phenotype
Female NebY2303H,Y935X mice were significantly smaller
than controls at 6 months, and similarly, NebY935X (+/−)
females weighed significantly less at both 3 months and
6months (Additional file 3a: Six month time point).
Body weights of male and female NebY2303H mice col-
lected at 3 months and 6months of age were not signifi-
cantly different to wild-type littermate controls.
Investigation of muscle function using grip strength test
only showed a deficit in muscle force in 6month female
NebY2303H,Y935X mice (Additional file 3b). There was no
distinction in force between wild-type controls and male
NebY2303H,Y935X mice as was also the case for NebY2303H or
NebY935X mice for either sex or time point analysed.
Investigating muscle function using voluntary running
wheels yielded inconclusive results due to high variability
Fig. 4 NebY2303H,Y935X mice have significantly smaller myofibre diameters at 9 months of age. a-d MHC fibre types (I, IIA, IIB and mixed I/IIA and IIA/IIX)
from 9-month-old female NebY2303H,Y935X extensor digitorum longus (EDL) and soleus (SOL) were counted and fibre diameters measured. a All
myofibres except MHC type I were smaller in EDL from NebY2303H,Y935X mice compared with age matched wild-type littermates. b All fibres in SOL
were smaller in NebY2303H,Y935X mice, although no mixed MHC type I/IIA were identified in this cohort. c, d Fibre-type proportions were measured in
EDL (d, n = 3) and SOL (e, n = 3) but were not significantly different. Unpaired Mann-Whitney, *p < 0.05; **p < 0.005; ***p < 0.0005; ****p < 0.0001
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in each cohort analysed. While female NebY2303H,Y935X
mice displayed a significantly decreased performance in
daily distance, average speed and maximum speed at 6
months (Additional file 3c) these results were not ob-
served at the 3month time point, or in male mice at either
time point. Similarly, no significant differences were seen
in any parameter for male and female NebY2303H or
NebY935X mice at either time point. Some mice were cap-
able of running distances comparable to wild-type litter-
mate controls while others did not run at all. Therefore,
this may not be the most accurate measure of muscle
function for these mouse models.
No significant differences were seen for any cohort
that underwent rotarod analysis.
Discussion
As most NM patients with NEB mutations have a com-
pound heterozygous genotype and do not have a severe
phenotype, there is a need for an animal model that accur-
ately represents these features. The only murine model to
Fig. 5 Whole-muscle physiology experiments showed the NebY2303H,Y935X EDL muscle was susceptible to eccentric contraction-induced damage.
a, b Whole-muscle in vitro contractile analysis of extensor digitorum longus (EDL) and soleus (SOL) from male mice at 7 months of age showed a
significant deficit in normalised force production in NebY2303H,Y935X at low-stimulation frequencies. c, d EDL NebY2303H,Y935X muscle was more
susceptible to damage by eccentric contractions involving stretches to 120 to 140% of Lo than wild type. e, f Transient stretch-induced force
responses were higher in NebY2303H,Y935X EDL muscles compared with wild type, suggesting increased stiffness in NebY2303H,Y935X EDL muscles. In
contrast, transient stretch-induced force responses were lower in NebY2303H,Y935X SOL muscles compared with wild type, suggesting greater
compliance in NebY2303H,Y935X SOL muscles. n = 7, Two-way ANOVA, *p < 0.05; **p < 0.005; #p < 0.0005; ¤p < 0.0001
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date that has harboured a mutation akin to those found in
human patients has been the NebΔexon55 mouse [61] with
homozgyous deletion of exon 55. However the NebΔexon55
model had a very severe NM phenotype, with mice exhibit-
ing dramatic growth retardation and death occurring within
the first week of life. This phenotype was very different
from the observed phenotype of patients with the equiva-
lent homozygous exon 55 deletion [43]. Contrastingly, an-
other murine model with a large deletion of the C-terminus
of nebulin, NebΔSH3, had no observable disease phenotype
[90]. The NebΔ163–166 mouse that lacks both the C-terminal
domains, SRC homology 3 domain (SH3) and serine rich
region (SRR), had a moderate myopathic phenotype [46].
All other published Neb murine models have been knock-
outs (KO) of Neb [8, 47, 89] and are not genetically appro-
priate models for investigation, as a complete absence of
nebulin expression has never been identified in a NEB-NM
patient [44]. Muscle defects in mice often result in no
abnormal phenotype or less severe clinical phenotypes than
in humans [15], which complicates developing a mouse
model with a milder phenotype. However, to effectively
study nebulin function and the pathogenesis of NEB-NM, a
model with a longer lifespan is needed. To this end, we
have characterised a murine model with a compound het-
erozygous Neb mutation genotype.
NebY2303H,Y935X mice survive to adulthood and in the
current study were all sacrificed by 1 year of age, which
is equal to approximately 40 years in humans [21]. This
finding aligns with the knowledge that most patients
with milder forms of NM do not have an obviously
shortened life expectancy [73]. NM patients with two
truncating, i.e. frameshift or nonsense mutations in con-
stitutively spliced exons 5′ of exon 180 have not been
identified, suggesting that a complete loss of nebulin is
not compatible with human life. In the case of two trun-
cating mutations being present, either both or at least
Fig. 6 Single myofibre measurements show reduced force, slower ktr, and normal thin filament length. a In single-myofibre physiology
measurements 6-month-old male NebY2303H,Y935X mice had lower mean specific force compared with wild-type littermate controls. b Additionally,
the mean ktr (tension redevelopment) was slower in Neb
Y2303H,Y935X mice, however, c V0 was unaffected. These results indicate a potential
alteration of myosin cross-bridge kinetics underlying the force depression. Welch’s T-test, *p < 0.05. d The thin filament length was not altered in
NebY2303H,Y935X mice
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one is in an alternatively spliced exon [44]. The
NebY935X(+/+) mice, with two loss-of-function alleles, are
expected to have complete loss of the nebulin protein,
and, indeed, the phenotype is early lethal. This is also in
line with previous studies using the Neb-KO models [8,
89]. The total Neb transcript level was close to normal
in the muscles of heterozygous Neb-KO mice [25], des-
pite genetically only having 50% of Neb. Furthermore,
no differences in total protein levels were detected in
heterozygous Neb-KO mice, suggesting a compensation
mechanism in the wild-type nebulin expression. Only
50% of nebulin RNA was expressed in NebY2303H,Y935X
mice and all of these transcripts were expected to con-
tain the missense mutation. Expression of low levels of
truncated proteins from transcripts escaping the
nonsense-mediated decay pathway cannot, however, be
excluded. In rare autosomal dominant cases, a truncated
nebulin protein seems to act in a dominant-negative
way, contributing to the disease phenotype [33]. Despite
the lower level of transcript expressed, the total nebulin
protein levels were not found to be decreased in the
novel mice studied, indicating a compensation at the
protein level from the transcript expressed. Lower levels
of nebulin have been seen in some, but not all, NM pa-
tients and mice [42, 57, 61, 63], suggesting that a reduc-
tion in nebulin protein level is not always associated
with the NM phenotype. The differences in nebulin
levels across NM patients and mouse models indicate
another potential pathogenetic mechanism, i.e. the lower
protein level may also contribute to the cascade of
events leading to NM. As the NebY2303H mice, with
homozygous missense mutations, had no clear disease
phenotype, a currently unknown additional mechanism
must play a role in the pathogenesis of the NM pheno-
type in the compound heterozygous model.
The missense variant changes a perfectly conserved
amino acid (p.Tyr2303His) in one of the known canonical
actin-binding sites (SDxxYK) in super repeat eight (S8),
which in human nebulin is known to bind actin weakly
[39]. It has been hypothesised that a missense change in
an actin-binding site is potentially pathogenic [44], and
that a mismatch between nebulin and actin may increase
susceptibility to proteolysis [62]. It is also possible that a
missense variant in a weakly binding repeat could
strengthen actin binding, thus disrupting the dynamic
movement of the thin filament proteins in muscle con-
traction. In compound heterozygous NM patients a mis-
sense variant in NEB is usually coupled with another,
more disruptive mutation [44], as is the case with the
NebY2303H,Y935X mice. The exact missense change
p.Tyr2303His (corresponding to p.Tyr2308His in the hu-
man protein, NP_001258137.1) has not been described in
patients. However, the tyrosine in question is 100% con-
served, not only across all of the over 200 actin-binding
sites in nebulin, but also across species, highlighting its
importance. According to our records, there are six cases
with a combination of a missense variant affecting the
tyrosine in another conserved actin-binding site, coupled
with a nonsense, frameshift or a splice site change in the
other allele [44]. Five out of six of these patients presented
with typical NM, and one out of six with a mild form of
NM. In homozygous form, missense variants lead to a dif-
ferent disease entity, distal nebulin myopathy [84]. As
many variant combinations are unique to NM families,
genotype-phenotype correlations are difficult to establish.
To study disease pathogenesis, a model with a combin-
ation of a missense and nonsense mutation is ideal for
representing the mild to moderate NM phenotype.
Nemaline bodies are the defining pathological feature
in the skeletal muscles of NM patients, regardless of
genetic cause, although their abundance does not correl-
ate with disease severity [6, 16, 72]. The skeletal muscles
of NebY2303H,Y935X mice exhibit nemaline bodies, thereby
confirming that they are a mouse model of NEB-NM
disease. Nemaline bodies were present in NebY2303-
H,Y935X mouse muscles at the age of 4 months, which is
the earliest time point studied histologically. Proteins
originating from the thin filament or Z disc are known
components of nemaline bodies [86], which is consistent
with the presence of filamentous actin and alpha-actinin
in the nemaline bodies found in NebY2303H,Y935X mice.
Variance in distribution of nemaline bodies between
skeletal muscles is often seen in NEB-NM patients [78],
and they are most abundant in diaphragm, tongue and
masseter [23, 35, 50, 53, 79, 82]. Nemaline bodies in
NEB-NM patients are found in both fast and slow myofi-
bres, but they may only be present in a limited area of
the sample [78, 86]. Similarly, in NebY2303H,Y935X mice,
the aggregates were not evenly distributed within skel-
etal muscles. In contrast to the majority of NEB-NM pa-
tients, nemaline bodies in NebY2303H,Y935X mice were
preferentially localised in fast, glycolytic fibres (especially
in MHCIIB fibres, not found in human limb muscle),
whereas no nemaline bodies were found in slow myofi-
bres. This may explain the lower abundance of nemaline
bodies in the NebY2303H,Y935X muscles with fewer glyco-
lytic myofibres, i.e. soleus and diaphragm. However, it
does not explain the absence in the tibialis anterior with
the same fibre-type proportions as the extensor digi-
torum longus (MHCIIB make up 70% of total muscle fi-
bres [90]). The reason for these differences between
NebY2303H,Y935X mice and NEB-NM patients remains to
be elucidated. Skeletal muscle biopsies from NEB-NM
patients often show type I myofibre atrophy or hypotro-
phy, combined with type I fibre predominance, and type
II hypertrophy is occasionally observed [78]. Rare cases
with type II atrophy have also been encountered [86].
Despite not being significantly different, NebY2303H,Y935X
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mice showed a trend towards type I fibre predominance
in soleus. The same trend towards more oxidative myofi-
bre types in the soleus was also observed in the condi-
tional Neb-KO mouse model [47]. MHCIIA and IIB
fibres were significantly smaller, in contrast to most hu-
man nemaline patients. Additional signs of skeletal
muscle damage in NebY2303H,Y935X mice included the
presence of split myofibres, internal nuclei and occa-
sional fatty infiltration in quadriceps muscles. This is
similar to that seen in NM patients over time [69]. A
small number of patients with NEB mutations have been
reported to have cores within their skeletal muscles, with
some having a combination of a greater number of cores
and nemaline bodies (and hence their disorder becoming
known as “core-rod myopathy” [86]). Cores have also
been identified in distal NM with NEB mutations [76],
and in NM patients with RYR1, KBTBD13, CFL2 [86]
and ACTA1 mutations [30].
Muscle defects in mice often result in no abnormal
phenotype or less severe clinical phenotypes than in
humans [2, 9, 17, 28]. Several factors may contribute to
this, e.g. differences in body mass between human and
mouse, bipedal versus quadrupedal movement, the resili-
ent nature of mice, or other factors that differ between
mice and humans. A thorough investigation of the
in vivo phenotype revealed only minor differences be-
tween the mouse strains studied. Indeed, most of the re-
sults in the exercise tests remained comparable with
wild type, and large sample sizes were required to reach
the occasional significance. Overall, the results of the ex-
ercise performance were too mild and variable to be
used as a reliable measure of the disease phenotype.
However, the whole muscle experiments in vitro re-
vealed that the extensor digitorum longus and soleus
muscles displayed significant rightward shifts of their
force-frequency relationships at lower stimulation fre-
quencies, which is indicative of reduced Ca2+ sensitivity.
This has been reported in muscle from patients with
NM, including those with NEB-NM [62]. Extensor digi-
torum longus from NebΔSH3 mice also displayed a re-
duced relative force at lower stimulation frequencies
in vitro [90]. Similarly to the NebY2303H,Y935X mice, this
mouse model had no visible phenotype in vivo, despite
lacking the entire C-terminal SH3 domain of nebulin,
which has been thought to anchor nebulin to the Z disc,
among other roles. In contrast to the NebY2303H,Y935X
mice, the NebΔSH3 mice exhibited no histological or ul-
trastructural changes. As the NebY2303H,Y935X mice re-
capitulate several aspects of human NEB-NM, it is an
important model for studying nebulin function and dis-
ease pathogenesis, despite the mild clinical phenotype.
Whole muscle physiological studies on NebY2303H,Y935X
mice indicated increased susceptibility to contraction-
induced damage, which potentially occurs when a muscle
is stretched as it is contracting (e.g. when people walk
downhill). This has also been reported in NebΔSH3 mice
[90]. Additionally, we found evidence indicating a decrease
in stiffness in the soleus muscles from NebY2303H,Y935X
mice compared with wild-type mice, which is consistent
with recent reports showing that stiffness is reduced in
slow muscles from nebulin knock-out mice [31]. In con-
trast to this, our results also showed that extensor digi-
torum longus muscles from NebY2303H,Y935X mice are
significantly stiffer than those of wild-type mice. This dif-
ference in the effects of the combination of the NebY2303H
and NebY935X variants in fast and slow muscles could be
due to differences in the effects of one or both variants on
the function of the shorter nebulin isoform found in fast
myofibres [67]. An increase in stiffness can also be associ-
ated with splitting of myofibres (as often seen over time in
NM patients [85]), and were occasionally seen in the ex-
tensor digitorum longus and quadriceps of NebY2303-
H,Y935X mice. This may suggest that the increased stiffness
occurs predominantly in the fast twitch muscles, as no
split myofibres were identified in the soleus. The missense
change p.Tyr2303His could potentially affect the inter-
action between nebulin and actin, resulting in the in-
creased stiffness observed in the extensor digitorum
longus muscle of the NebY2303H,Y935X mice. Further studies
are needed, however, to elucidate the exact mechanism by
which stiffness is increased.
Shortened thin filaments have been seen in several of
the previous Neb mouse models [8, 47, 61, 89], and in
some, but not all NEB-NM patients [87], leading to the
hypothesis that the reduction is mutation specific [57,
87]. Shortened thin filaments are thought to contribute
to the force deficit observed in the corresponding mouse
models [47]. However, as some patients with mutations
in NEB have displayed significant force deficits with nor-
mal thin filament lengths, other mechanisms must also
affect force production [87]. Similarly, single myofibres
from NebY2303H,Y935X tibialis anterior muscles had lower
maximum force production, yet no change in thin fila-
ment length. No difference in maximum force was de-
tected at a whole muscle level (extensor digitorum
longus and soleus) for NebY2303H,Y935X mice, and thus it
is likely that the calcium transient and/or the muscle
architecture (e.g. pennation angle, quantity of non-
contractile material) are recompensing for the force def-
icit detected at the myofilament level.
Taken together, our data suggest that the nebulin de-
fects harboured by these mice alter myosin binding to
actin (potentially a slower attachment rate), thus disrupt-
ing cross-bridge cycling and ultimately perturbing force
production. Altered myosin cross-bridge kinetics has fre-
quently been found to underly force depression in NM
models [88]. Force generated per cross-bridge, and the
number of strongly bound cross-bridges both contribute
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to the force generated at a given overlap between the fila-
ments. Cross-bridge cycling kinetics determine both of
these quantifiers by modulating the time spent in the
strongly bound state. Chandra and co-workers found that
nebulin does not affect the force produced per individual
cross-bridge in the Neb-KO mouse model [12]. Our re-
sults corroborate this, as decreased time spent by
individual myosin molecules in a strongly attached force-
producing conformation was observed in the NebY2303-
H,Y935X mice. These physiological attributes detected in
skeletal muscles of NebY2303H,Y935X align with previous
measurements of samples from NEB-NM patients [57].
Conclusions
Characterisation of phenotypic aspects of NebY2303H,Y935X
mice with compound heterozygous Neb mutations, like
most NEB-NM mutations, has determined that they are a
suitable murine model of NEB-NM. They exhibit nema-
line bodies within their skeletal muscles and have several
other histological and physiological parameters resembling
NM. These findings make NebY2303H,Y935X mice the most
appropriate mouse model of NEB-NM thus far. Despite
the mild in vivo phenotype, the NebY2303H,Y935X mice,
along with their corresponding parental lines that carry ei-
ther the missense or the nonsense mutation, will be useful
in deciphering nebulin function and the pathogenetic
mechanisms of NEB-NM. Additionally, they may consti-
tute a good animal model for primary myosin motor dys-
function, and are likely to be valuable for the assessment
of potential therapeutic approaches for NEB-NM.
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